Creso Pharma Limited (ASX: CPH) had made an announcement related to the approval which has been provided by Israeli Parliament with the help of the press release. As per the press release dated January 2, 2019, the company had stated that the approval has been given with respect to medicinal cannabis export. Considering the changes which have been done, Israel would now be involved in global medicinal cannabis industry after getting the Israeli Cabinet sign off. Talking about the Creso Pharma, it happens to be in the robust position to reap the benefits of the changes with the help of 74% holding which it has in Joint Venture or JV with Cohen nurseries. Cohen Propagation Nurseries happens to be the family business which was set up in the year 1958. Its products possess hygiene, sterility as well as they are of high quality.
It would also be of interest to the market players that the only handful of companies which are being listed on the Australia Securities Exchange are engaged in carrying out activities in Israel and Creso Pharma happens to be one of them. Also, only the couple of companies are regarded as the Licensed Producers in Canada which are having the Israeli strains access and Creso is also one of them. Let us now have a look at the management viewpoints.
According to the key executive of Ministry of Health’s Medical Cannabis Unit, in the present scenario, there happen to be over 110 clinical trials which are focused on the cannabis and which are ongoing in Israel. The substantial part of the studies is being taken care of by the Israeli government in terms of the financing.
The top management of Creso Pharma Limited reflected favorable news with respect to the changes which have been done. They have stated that now the last legal hurdle with respect to the medicinal cannabis exports has also been removed and the company would now be working to tap the benefits of Israel’s technology as well as its access to the medicinal cannabis which have been researched and which are of high-quality.
The press release which was issued also stated that, with regards to human and animal CBD supplement market, Creso Pharma is progressing on the path to be a larger player on the global basis.
Let us now see how the stock of CPH has been performing today. At the time of writing, Creso Pharma is trading in green and is having the price of A$0.560 per share which reflects an upside of A$0.070 per share or 14.286%. The market capitalization of Creso Pharma Limited stood at $60.85 million. The company’s stock price is trading towards the lower level. Talking about the past performance of Creso Pharma, it has delivered the return of -24.62% in the span of the previous six months. However, in the time span of the previous three months and one month, it had delivered -10.91% and 15.29% return, respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.